Shire to pay $4.2bn for rare disease firm ViroPharma
This article was originally published in Scrip
Executive Summary
Shire has agreed to pay $4.2bn to acquire ViroPharma, which sells the orphan drug Cinryze. The prophylactic treatment is for the rare disease hereditary angioedema (HAE).